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INTRODUCTION
The risk of graft rejection after allogeneic marrow
transplantation is increased when the donor is not HLA-
matched with the recipient [1-4]. The presence of an HLA-
A or HLA-B disparity in the donor has been shown to
increase the risk of graft failure [3,5], and recipient-derived
cytolytic T lymphocytes that recognize HLA-A or -B anti-
gens of the donor have been isolated from some patients at
the time of graft rejection [6-8]. HLA-C disparity in the
donor has also been associated with an increased risk of
graft failure [9,10], but previous studies have not determined
whether T cells or natural killer (NK) cells of the recipient
are responsible for rejection of HLA-C–disparate hemato-
poietic stem cells. In this report, we characterize the effector
cells isolated from a patient who rejected an HLA-Cw4–
disparate marrow graft. Our results suggest that cytotoxic
T cells of the recipient can cause rejection through recogni-
tion of HLA-C alloantigens.
CASE REPORT
The patient was a 42-year-old man with chronic
myeloid leukemia in chronic phase. His HLA type was
A*2402/3201, B*5101 (Bw4)/4002 (Bw6), Cw*02022/1502,
DRB1*1301/1401, and DQB1*0503/0603. After treatment
with cyclophosphamide (60 mg/kg on each of 2 successive
days) and 13.2 Gy fractionated total body radiation, he
received CD4-depleted marrow from an unrelated donor
[11]. The processed graft contained 0.61 × 104 CD4 cells,
3.1 × 106 CD8 cells, 2.8 × 107 nucleated cells, and 1.7 × 106
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readily detectable in other blood samples drawn before or after the transplantation, indicating that this clone was
only 1 of many recipient-derived T cells that recognized HLA alloantigens of the donor. These results demonstrate
the role of the HLA-C locus in T-cell–mediated alloimmune responses and add to emerging evidence that indicates
the need to evaluate HLA-C compatibility in selecting hematopoietic stem cell donors for patients who have an
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CD34 cells per kg recipient body weight. Cyclosporine and
methotrexate were given for immunosuppression after the
transplantation. The donor’s HLA type was A*2402/3201,
B*3501 (Bw6)/4002 (Bw6), Cw*02022/0401, DRB1*1301/1401,
and DQB1*0503/0603. The patient had received transfu-
sions before the transplantation, but crossmatch tests with
patient serum and cells of the marrow donor and cells from
third party donors showed no indication of sensitization.
There was no evidence of engraftment after the ﬁrst trans-
plantation. After immunosuppressive treatment with a
CD3-speciﬁc monoclonal antibody and high-dose glucocor-
ticoids, the patient received a second transplant of growth
factor–mobilized peripheral blood stem cells from the same
donor on day 49 after the ﬁrst transplantation, again with-
out engraftment. The patient received a third transplant of
marrow from another donor on day 102 after the ﬁrst trans-
plantation, but he died 10 days later.
METHODS
Informed consent was obtained from the patient for col-
lection of blood samples before the ﬁrst transplantation and
on days 27, 66, 85, and 96 after the ﬁrst transplantation.
T-cell clones that recognized donor cells were isolated
from a blood sample obtained on day 85 after the ﬁrst trans-
plantation (day 36 after the second transplantation).
Mononuclear cells from the blood were cultured with irradi-
ated donor peripheral blood mononuclear cells (PBMNCs)
in RPMI-1640 medium containing 15% pooled male serum
and 10 U/mL recombinant interleukin (IL)-2. T cells were
subsequently cloned from cell lines by limiting dilution
under stimulation with CD3-speciﬁc antibody OKT3 in the
presence of IL-2 and irradiated peripheral blood mononu-
clear feeder cells from unrelated individuals. T-cell clones
were expanded in the presence of antibody OKT3, IL-2,
and feeder cells as described elsewhere [12].
Mononuclear cells and T-cell clones were tested for
cytolytic activity against Epstein-Barr virus–transformed
B cells or phytohemagglutinin-stimulated lymphoblasts
from the patient, donor, and unrelated individuals by using
4-hour 51Cr-release assays [13]. NK-sensitive K562 cells,
HLA class I–negative 721.221 cells, and 721.221/Cw*0401-
transfectant cells were also used as targets in cytotoxicity
assays. Mononuclear cells and T-cell clones were stained by
2-color direct immunoﬂuorescence with ﬂuorescein isothio-
cyanate or R-phycoerythrin–conjugated monoclonal anti-
bodies against human CD3, T-cell receptor αβ, CD4, CD8,
CD16, and CD56 (Becton Dickinson, San Jose, CA). The
stained cells were analyzed by ﬂow cytometry with the use
of a FACScan and CellQuest software (Becton Dickinson).
T-cell–receptor-BV complementarity-determining region 3
(CDR3) segments were amplified from complementary
DNA (cDNA), and the length distributions of amplified
products were analyzed according to methods described
previously [14].
To identify the T-cell–receptor-BV genes expressed in
cloned T cells, total RNA was reverse-transcribed into
cDNA for amplification with 24 BV sense primers [14]
each paired with a BC antisense primer. Amplified prod-
ucts were purified by QIAamp Gel Extraction Kit
(QIAGEN, Santa Clarita, CA) and sequenced with
Thermo Sequenase (Amersham, Cleveland, OH). The
antisense primer 5′-GCTGGGGCTGATTCAAAGA-3′
was designed to span the DJ region for use in a highly sen-
sitive assay to detect the clonotypic T-cell–receptor gene
rearrangement. Samples of cDNA corresponding to 1.0 ×
105 cells were tested by amplification with the BV8S1
sense primer (5′-CGGGGACTGGAGTTGCT-3′) and
the clone-specific antisense primer at final concentrations
of 0.5 µM. The ampliﬁed products were electrophoresed in
a 2% agarose gel, blotted onto nylon membranes, and
hybridized with 25 pmol of BV8-specific oligonucleotide
that was 3′-labeled with fluorescein-11-deoxyuridine
triphosphate. Ampliﬁed products were incubated with anti-
ﬂuorescein antibody conjugated to horseradish peroxidase,
which catalyzed luminol to emit a chemiluminescent signal
that was detected on film (ECL Direct Labelling and
Detection System; Amersham).
RESULTS
Assessment of informative variable-number tandem-
repeat markers showed that nearly all PBMNCs in the
patient at the time of initial engraftment failure were of
recipient origin, confirming that graft rejection had
occurred. Lymphocytes from the patient were 99% CD3+
after the first rejection and 98% CD3+ after the second
rejection. Among the CD3+ T cells, 90% or more were
CD8+ and only 1% to 9% were CD4+. Only 1% of the lym-
phocytes expressed the NK markers CD16 or CD56.
Results of further in vitro studies with cells from the
patient are summarized in Table 1. Without any in vitro
stimulation, mononuclear cells obtained on day 27 after the
ﬁrst transplantation had cytolytic activity against donor cells
but not against recipient cells (Figure 1A). The patient’s cells
showed similar cytolytic activity against third-party cell lines
sharing HLA-B*3501 and HLA-Cw4, which were the mis-
matched antigens of the donor. Cytolytic activity against a
third-party cell line that expressed HLA-B*3503 without
HLA-Cw4 was lower than against cell lines that expressed
HLA-B*3501 and HLA-Cw4. Cytolytic activity against
K562 cells was <10%. Without any in vitro stimulation,
mononuclear cells obtained on day 96 after the first trans-
plantation (day 47 after the second transplantation) also
had cytolytic activity against donor cells but not against
any of 4 cell lines that lacked HLA-B35 and HLA-Cw4 (Fig-
ure 1B). The cytolytic activity against donor cells supports
the hypothesis that graft failure in this patient was caused by
Table 1. Summary of Results*
Unstimulated Clone 3.1 
Cw4-Specific T-Cell–Receptor
Day Cytotoxicity Amplification
27 Positive Weak
66 (17) Not tested Weak
96 (47) Positive Not tested
*Data in the table summarize results of testing blood samples drawn
on the indicated day after the ﬁrst (or second) transplantation. Clone
3.1 was isolated from a blood sample drawn on day 85 after the ﬁrst
transplantation (day 36 after the second transplantation).
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a cellular immune mechanism that involved recognition of
the donor HLA-Cw4 and HLA-B35 alloantigens.
We analyzed the length distributions of ampliﬁed T-cell–
receptor BV CDR3 segments to determine whether the
graft rejection could be explained by pauciclonal expansion
of a limited number of HLA-Cw4–speciﬁc T cells from the
recipient. In a cDNA sample from blood obtained from the
recipient on day 27 after the first transplantation, CDR3-
length distributions generally showed distortions in only
1 or 2 peaks (Figure 2). These results indicate that recipient
T cells with a broad repertoire of antigen receptors survived
the pretransplantation conditioning regimen.
Four primary T-cell lines were generated from a blood
sample obtained from the patient on day 85 after the ﬁrst
transplantation. These T-cell lines were CD8+ and had
cytolytic activity against donor cells. Six CD8+ T-cell clones
were isolated by limiting-dilution culture from 1 of the T-cell
lines. All 6 T-cell clones expressed the same BV8S1 T-cell–
receptor rearrangement as determined by sequencing ampli-
fied cDNA. A T-cell clone designated as 3.1 was tested
further. Clone 3.1 and the cell line from which this clone
was derived expressed HLA-B*5101 but not HLA-B*3501,
indicating that these cells had originated from the recipient
and not from the donor.
Clone 3.1 had cytolytic activity against all 16 HLA-
Cw4–positive target cells tested, including 7 that were
HLA-B35–negative (Table 2). Clone 3.1 did not lyse cells
of the patient, K562 cells, or any of the 4 cell lines that
were HLA-Cw4–negative and B*3501- or B*3503-positive.
Clone 3.1 also did not lyse 10 of 13 cell lines that were
HLA-Cw4–negative and B35-negative. Because clone 3.1
had cytolytic activity against 3 HLA-Cw4–negative cell
lines in the panel, we tested the HLA-class I–negative cell
line 721.221 transfected with HLA-Cw*0401. Clone 3.1
had cytolytic activity against the 721.221/Cw*0401 trans-
fectant cells but not against the wild-type 721.221 cells
(Figure 3). Taken together, these ﬁndings demonstrate that
clone 3.1 recognizes a native epitope of HLA-Cw*0401
molecules, with additional cross-recognition of other unde-
ﬁned antigens.
Figure 1. Peripheral blood mononuclear cells isolated from the patient
at the time of rejection showed spontaneous cytotoxic activity speciﬁc
for HLA-Cw4 and HLA-B35 alloantigens of the donor. Blood cells
were obtained from the patient on day 27 (panel A) and on day 96 after
the ﬁrst transplantation (panel B). Cytolytic activity was tested without
prior in vitro stimulation. A, Target cells included lymphoblastoid cell
lines derived from the donor, the recipient, 2 HLA-B*3501–positive/
Cw4-positive individuals, and 1 HLA-B*3503–positive/Cw4-negative
individual. Cells of the patient were also tested for cytolytic activity
against natural killer–sensitive K562 cells. The effector-to-target ratio
was 40:1. B, Target cells included phytohemagglutinin-stimulated
lymphoblasts obtained from the donor (!) and from 4 HLA-B35–
negative/HLA-Cw4–negative individuals (").
Figure 2. Length distributions of T-cell–receptor-BV complementar-
ity-determining region 3 segments amplified with complementary
DNA (cDNA) prepared from a blood sample obtained on day 27 after
the ﬁrst transplantation showed a broad repertoire of antigen receptors.
The 3-base-pair spacing between peaks results from survival of T cells
with productive T-cell–receptor-B gene rearrangements. In healthy
individuals, peak heights approximate a gaussian distribution. Distor-
tions from a gaussian distribution reflect expanded populations of
T cells having T-cell–receptor gene rearrangements of the same
length. The arrow above the BV8* proﬁle indicates the length of the
T-cell receptor expressed by clone 3.1, as determined by an experiment
in which cDNA from the clone was mixed with cDNA from the blood
sample on day 27. The arrow above the BV8 proﬁle indicates the cor-
responding peak in the ampliﬁed product obtained with cDNA from
the blood sample without cDNA from clone 3.1 added.
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We further evaluated whether clone 3.1 could be iden-
tified directly in blood samples from the patient. For this
purpose, we determined that clone 3.1 expresses a BV8S1
T-cell receptor and identified the rearranged sequence that
encodes this receptor. With this information, we designed
oligonucleotide primers that amplify the DJ segment of
the T-cell–receptor mRNA specific for clone 3.1. Ampli-
fied products were detected by hybridization with a BV8-
specific probe.
The T-cell–receptor sequence speciﬁc for clone 3.1 was
easily detected in cDNA from 10 cells of clone 3.1 mixed
with 1.0 × 106 PBMNCs pooled from 3 unrelated individu-
als (Figure 4, lane 3). This sequence was not detected in
PBMNC cDNA from 3 unrelated individuals (Figure 4,
lane 4) or from the donor or from the patient before trans-
plantation (Figure 4, lanes 5 and 6). Likewise, the sequence
was not detected in cDNA from PBMNCs that were
obtained from the patient before transplantation and stimu-
lated twice in vitro with irradiated PBMNCs from the
donor during culture for a total of 21 days (data not
shown). Very weak hybridization was detected in 2 of
3 experiments with cDNA from blood cells that were
obtained from the patient on day 27 after the first trans-
plantation (Figure 4, lane 7) and in each of 3 experiments
with cDNA from blood cells that were obtained on day 66
after the ﬁrst transplantation (day 17 after the second trans-
plantation) (Figure 4, lane 8). The clone 3.1 T-cell–receptor
rearrangement that was ampliﬁed with BV8- and BJ-speciﬁc
primers comigrated with the peak identified by the arrow
in Figure 2. No hybridization was detected in any of
3 experiments with cDNA from a T-cell line derived from a
blood sample drawn on day 96 after the ﬁrst transplantation
(day 47 after the second transplantation) (Figure 4, lane 9),
even though this cell line had cytolytic activity against
donor cells. Unfortunately, no cells or cDNA from the blood
sample used to generate clone 3.1 were available for testing
in this assay.
The nearly undetectable signal from an extremely sensi-
tive assay to detect the clonotypic T-cell–receptor gene
rearrangement suggests that the HLA-Cw*0401–specific
clone 3.1 T cell was present at frequencies much lower than
1 × 10–5 in the blood samples obtained on days 27 and 66 after
the ﬁrst transplantation. Thus, it is unlikely that the cytolytic
activity detected in the blood sample obtained on day 27
resulted exclusively from clone 3.1. We postulated that anneal-
ing of the clone-speciﬁc antisense primer with a DJ segment
encoding an amino acid sequence identical to the clone
3.1–specific sequence but differing in nucleotide sequence
from the clone 3.1–specific DJ segment by 1 or possibly
2 bases might explain the hybridization consistently observed
with the sample obtained on day 66 (Figure 4, lane 8).
No ampliﬁcation was detected when cDNA from blood
cells obtained on day 66 was tested with the BV8S1 sense
primer paired with an antisense primer in which T, C, or G
was substituted at position 17 of the 19-bp clone-speciﬁc anti-
sense primer or when G was substituted at position 16 of the
Table 2. Cytolytic Activity of Clone 3.1 According to Expression of HLA-
B35 and HLA-Cw4 in a Panel of Cells From 33 Individuals (HLA-Cw4+
[n=16] and HLA-Cw4– [n=17])*
E:T of 25:1 E:T of 50:1 
Target <10% Lysis ≥10% Lysis† <10% Lysis ≥10% Lysis‡
B35+/Cw4+ 0 9 0 9
B35–/Cw4+ 0 7 0 7
B35+/Cw4–§ 4 0 4 0
B35–/Cw4– 12 1 10 3
*Cytolytic activity was measured at 2 effector-to-target ratios (E:T)
by 4-hr 51Cr-release assays.
†Range, 12% to 52% lysis. 
‡Range, 12% to 59% lysis.
§One of these cell lines expressed HLA-B*3501, and the other
3 expressed HLA-B*3503.
Figure 3. Clone 3.1 showed cytotoxic activity against 721.221 cells
transfected with HLA-Cw*0401 (!) but not against untransfected
721.221 control cells (").
Figure 4. The clone 3.1–speciﬁc T-cell–receptor-BV gene rearrange-
ment was not readily detected in blood samples from the patient. Sam-
ples of complementary DNA (cDNA) corresponding to 1.0 × 105
peripheral blood mononuclear cells (PBMNCs) were tested by ampliﬁ-
cation with a T-cell–receptor-BV8S1 sense primer and a T-cell–
receptor-DJ antisense primer specific for clone 3.1. Amplified DNA
products were detected by blot hybridization with a T-cell–receptor-
BV8–speciﬁc probe. Lanes 1-3, cDNA from 1000, 100, or 10 clone 3.1
cells mixed with 1.0 × 106 PBMNCs pooled from 3 unrelated individu-
als; lane 4, cDNA from PBMNCs of 3 unrelated individuals; lane 5,
cDNA from PBMNCs of the donor; lane 6, cDNA from PBMNCs of
the patient before transplantation; lane 7, cDNA from PBMNCs of the
patient on day 27 after the ﬁrst transplant; lane 8, cDNA from PBMNCs
of the patient on day 66 after the ﬁrst transplantation (day 17 after the
second transplant); lane 9, cDNA from a T-cell line isolated from PBM-
NCs of the patient on day 96 after the ﬁrst transplantation (day 47 after
the second transplant).
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clone-speciﬁc antisense primer (data not shown). An ampliﬁed
product was detected when each of these antisense primers
was tested with cDNA from 100 cells of clone 3.1 mixed with
1.0 × 106 PBMNCs pooled from 3 unrelated individuals. No
ampliﬁcation was detected when the BV8S1 sense primer was
paired with antisense primers in which G was substituted at
position 16 and T, C, or G was substituted at position 17 (data
not shown), and no ampliﬁed products were detected when
the 3 doubly substituted primers were tested with the mixture
containing clone 3.1 cDNA (data not shown). We conclude
that weak ampliﬁcation with the CDR3 antisense primer was
not caused by annealing with any of the highly similar
rearranged DJ segments that could encode a T-cell–receptor-β
chain identical to the clone 3.1 T-cell–receptor-β chain.
DISCUSSION
We describe a patient who rejected a T-cell–depleted
HLA-Cw4-disparate marrow graft. PBMNCs obtained
from this patient after the rejection were predominantly
CD8+ and showed spontaneous cytolytic activity speciﬁc for
the HLA-Cw4 alloantigen of the donor. In addition, we
recovered an HLA-Cw4–speciﬁc CD8+ T-cell clone from a
blood sample after the rejection. The BV8 T-cell–receptor
gene rearrangement expressed by this clone could not be
detected in a blood sample drawn before the transplantation
or in other blood samples drawn at earlier or at subse-
quent times after the transplantation. The absence of any
detectable increase in the peak corresponding to the clone
3.1 T-cell–receptor gene rearrangement within the CDR3
segments of BV8 T-cell–receptor genes also indicates that
this clone did not contribute signiﬁcantly to the peripheral
T-cell pool expressing BV8 T-cell receptors when rejection
ﬁrst became apparent. These results suggest that the clone
we isolated was only 1 member of a diverse population of
recipient-derived T cells that recognized HLA-Cw4 and
HLA-B35 alloantigens of the donor.
HLA-C molecules function as “killer inhibitory recep-
tors” for NK cells [15], and the absence of a recipient-type
HLA-C molecule on donor cells might make the donor cells
susceptible to attack by NK cells of the recipient. From cur-
rently available information about the regulation of NK
cells, however, NK-mediated rejection related to HLA-C
disparity would not have been expected in the case we
describe because both alleles in the donor and recipient have
Lys at position 80 [16]. These alleles bind KIR2DL1, the
inhibitory receptor expressed by NK1 cells. On the other
hand, NK-mediated rejection related to HLA-B disparity
could have occurred because the donor was HLA-Bw6
homozygous, whereas the patient was HLA-Bw4/Bw6 het-
erozygous. The HLA-Bw6 allele on donor cells cannot bind
to the HLA-Bw4–specific inhibitory receptor KIR3DL1
[17]. In the case we describe, the absence of NK cells and
the absence of NK activity in the blood on day 27 suggest
that NK cells were not involved in mediating graft failure
but do not exclude this possibility.
HLA-C molecules can also function as conventional
transplantation antigens, and the presence of an HLA-C
alloantigen might make the donor cells susceptible to attack
by alloreactive T cells of the recipient [18,19]. The HLA-
Cw4–specific spontaneous cytotoxicity of cells from the
patient supports the hypothesis that rejection was caused by
recipient T cells that survived the pretransplantation condi-
tioning regimen and responded to HLA-C alloantigens of
the donor. We infer that clone 3.1 was only 1 of many
recipient T cells that contributed to rejection by recogniz-
ing HLA-Cw4 alloantigens. These results add to emerging
evidence demonstrating the role of the HLA-C locus in
T-cell–mediated alloimmune responses. HLA-C compatibil-
ity should be evaluated in selecting stem cell donors for
patients who have an increased risk of rejection.
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